Sirolimus is effective in relapsed/refractory autoimmune cytopenias: Results of a prospective multi-Institutional trial

168Citations
Citations of this article
129Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Patients with autoimmune multilineage cytopenias are often refractory to standard therapies requiring chronic immunosuppression with medications with limited efficacy and high toxicity. We present data on 30 patients treated on a multicenter prospective clinical trial using sirolimus as monotherapy. All children (N = 12) with autoimmune lymphoproliferative syndrome (ALPS) achieved a durable complete response (CR), including rapid improvement in autoimmune disease, lymphadenopathy, and splenomegaly within 1 to 3 months of starting sirolimus. Double-negative T cells were no longer detectable in most, yet other lymphocyte populations were spared, suggesting a targeted effect of sirolimus. We also treated 12 patients with multilineage cytopenias secondary to common variable immunodeficiency (CVID), Evans syndrome (ES), or systemic lupus erythematosus (SLE), and most achieved a CR (N = 8). although the time to CR was often slower than was seen in ALPS. Six children with single-lineage autoimmune cytopenias were treated and only 2 responded. Sirolimus was well tolerated with very few side effects. All of the responding patients have remained on therapy for over 1 year (median. 2 years; range. 1 to 4.5 years). In summary, sirolimus led to CR and durable responses in a majority of children with refractory multilineage autoimmune cytopenias. The responses seen in ALPS patients were profound, suggesting that sirolimus should be considered as a first-line, steroid-sparing treatment of patients needing chronic therapy. The results in other multilineage autoimmunecytopenia cohorts were encouraging, and sirolimus should be considered in children with SLE, ES, and CVID.

Cite

CITATION STYLE

APA

Bride, K. L., Vincent, T., Smith-Whitley, K., Lambert, M. P., Bleesing, J. J., Seif, A. E., … Teachey, D. T. (2016, January 7). Sirolimus is effective in relapsed/refractory autoimmune cytopenias: Results of a prospective multi-Institutional trial. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2015-07-657981

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free